The need for new therapies to treat coronavirus patients has prompted an onslaught of advisories from FDA clarifying how sponsors should assess and implement changes necessary to fit this new reality.
Jill Wechsler
Advertisement
Jill Wechsler is ACT's Washington Editor
Articles by Jill Wechsler
February 09, 2017
Advertisement
Latest Updated Articles
- PDUFA Offers New Tools to Support Drug Development & Review
February 9th 2017
Advertisement
Advertisement
Trending on PharmExec
1
Novo Nordisk Responds to FDA’s Warning Letter Regarding 2025 PADE Inspection
2
Senate Democrats Expand Efforts to Expose Details of MFN Pharma Deals
3
When Ambition Meets Ambiguity: The Trends and Sentiments Shaping Biotech in 2026
4
JCA vs. Reality: Europe’s Push for Clinical Harmonization
5